Breast Cancer Research and Treatment

, Volume 12, Issue 1, pp 81–82 | Cite as

Comment on ‘Difference between R5020 and the anti progestin RU486 in antiproliferative effects on human breast cancer cells’

  • M. R. Mooore
  • P. Gill
  • F. Vignon
  • H. Rochefort
Correspondence

Keywords

Public Health Breast Cancer Cancer Cell Breast Cancer Cell Human Breast Cancer 

References

  1. 1.
    Hisson JR, Moore MR: Progestin effects on growth in the human breast cancer cell line T47D: possible therapeutic implications. Biochem Biophys Res Commun 145: 706–711, 1987PubMedGoogle Scholar
  2. 2.
    Manni A, Budger B, Wright C, Ahmed R, Demers LM: Effects of progestins on growth of experimental breast cancer in culture: interaction with estradiol and prolactin and involvement of the polyamine pathway. Cancer Res 47: 3066–3071, 1987PubMedGoogle Scholar
  3. 3.
    Robinson SP, Jordan VC: Reversal of the antitumor effects of tamoxifen by progesterone in the 7, 12-dimethylbenzan-thracene-induced rat mammary carcinoma model. Cancer Res 47: 5386–5390, 1987PubMedGoogle Scholar
  4. 4.
    Braunsberg H, Coldham NG, Leake RE, Wong W: Actions of a progestogen on human breast cancer cells: mechanisms of growth stimulation and inhibition. Eur J Cancer Clin Oncol 23: 563–571, 1987PubMedGoogle Scholar
  5. 5.
    Longman SM, Buehring GC: Oral contraceptives and breast cancer. In-vitro effect of contraceptive steroids on human mammary cell growth. Cancer 59: 281–287, 1987PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • M. R. Mooore
    • 1
  • P. Gill
    • 2
  • F. Vignon
    • 2
  • H. Rochefort
    • 2
  1. 1.Department of BiochemistryMarshall Univ. School of MedicineHuntingtonUSA
  2. 2.Inserm U 148MontpellierFrance

Personalised recommendations